Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week‐24 Results of a Phase 3, Randomized, Placebo‐Controlled Study
Alexis Ogdie, J F Merola, P. Mease, Christopher T Ritchlin et autres
OBJECTIVE: To evaluate the efficacy and safety of guselkumab, an interleukin-23p19 subunit inhibitor, in participants with active psoriatic arthritis (PsA) and inadequate response (inadequate efficacy and/or intolerance) to one prior tumor necrosis factor (TNF) inhibitor. METHODS: In SOLSTICE (phase 3b, randomized, multicenter, …
us, il (code pays fourni par la source)
1 citation
Arthritis & Rheumatology